iRhythm Holdings, Inc.
IRTCAbout the company
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
3 / 13
NEUTRAL / FAIL
Median fair value
$28.98
-68.5% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #1990 (Top 64.3%) | NEUTRAL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | -370.4% | N/A | N/A | N/A | -139.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-02-19 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-19 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 6✗ 29▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/13 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/13 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-59.4%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-7.7% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-44.6M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-21.8%✗Lynch> 15%EBIT / Enterprise Value-2.0%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-2.0%, ROC=-12.3%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-4.37%✗PiotroskiROA > 0ROA Change YoY-12.16% -> -4.37% (delta: +7.80%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=7.93%, ROA=-4.37%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY68.9% -> 70.6%✓PiotroskiImproved YoYPre-Tax Income / Revenue-4.4%✗Dreman>= 8%Net Income / Shareholders' Equity-21.8%✗Dreman> 12%Margin of SafetyP/B=19.4x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-70.8% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/12 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-5.7%✗Ackman>= 15%Net Income / Shareholders Equity-21.8%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-25.4% (2023) -> -7.7% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 67.3% -> 70.6%, operating margin -25.4% -> -7.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-1.27%; #3450/6340 (top 54.4%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+56.54%; #533/3702 (top 14.4%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity-21.79%; #3731/5226 (top 71.4%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0901; #3346/5884 (top 56.9%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio19.4x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-2.0%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-2.0%, ROC=-12.3%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)36.6x✗Dreman< 8xPrice / Book Value per Share19.4x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-2.4%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=1.1%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=19.4x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share85.7x✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($91.91)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-1.27%; #3450/6340 (top 54.4%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.0581; #4963/6449 (top 77.0%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share19.48x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-59.5%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.2800; #3413/5247 (top 65.0%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization+0.24%; #2493/4519 (top 55.2%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-20.24%; #3981/6202 (top 64.2%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 3✗ 10▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 18.7% vs Rev: 21.6%✓LynchInventory growth < Revenue growthEPS Growth Direction$-12.05 (2014) -> $-1.39 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/12 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth20.1%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 67.3% -> 70.6%, operating margin -25.4% -> -7.7%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR23.0%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts0% pass✗ 14▾
Split decision: 13 FAIL · 3 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #1990•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Valuation models0% pass✗ 2▾
IRTC overvalued: all 2 models price fair value below $91.91 (median $28.98)
Munger fair value$19.54✗Munger-370.4% margin vs $91.91Ackman fair value$38.42✗Ackman-139.2% margin vs $91.91 - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag IRTC's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities3.57✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-5.8x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Cash Flow20% pass✓ 3✗ 9▾
8 of 10 flag IRTC's cash flow — Buffett, Lynch, Dreman +5 more
Free Cash Flow Proxy$-44.6M✗BuffettPositive and growingFCF Positive and Growing$7.4M✗LynchPositive and growingOperating Cash Flow$80.9M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=7.93%, ROA=-4.37%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)36.6x✗Dreman< 8xP/E or FCF YieldFCF Yield=1.1%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive1/12 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap0.2%✗Ackman>= 4%Price / FCF per Share85.7x✗Ackman<= 25Positive Operating Cash Flow frequency2/12 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$7.4M✓Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization+0.24%; #2493/4519 (top 55.2%)✗OshaughnessyTop 10% of eligible cross-section - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag IRTC's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio3.57✓Graham>= 2.0ROIC (3-5 yr avg)-36.1%✗Buffett> 10%ROIC - WACC-46.1%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-12.3%✗Greenblatt> 25%Current Ratio Change YoY5.82 -> 4.63✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.64x -> 0.73x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities3.57✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-40.4%; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/3 years above 12% (latest -40.4%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 2.9% of shares last year, 4.0% issued over two.
- Buybacks
- $0
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.1Bcurrent | -- | -- | -- | $5.0Best. | $3.4Best. | $3.7Best. | $3.0Best. | $3.7Best. |
| Revenue | $854.0M↑22% | $221.6M↑15% | $224.2M↑20% | $199.4M↑26% | $747.1M↑26% | $591.8M↑20% | $492.7M↑20% | $410.9M↑27% | $322.8M |
| Operating Income | -$49.0M↑23% | -$32.6M↓286% | -$2.5M↑86% | -$16.2M↑50% | -$57.4M↑50% | -$115.5M↑8% | -$125.2M↓10% | -$113.8M↓14% | -$99.9M |
| Net Income | -$38.6M↑25% | -$29.9M↓473% | -$381.0K↑97% | -$13.9M↑55% | -$44.6M↑61% | -$113.3M↑8% | -$123.4M↓6% | -$116.2M↓15% | -$101.4M |
| EPS (Diluted) | -- | $-0.90↓463% | $-0.01↑98% | $-0.43↑56% | $-1.39↑62% | $-3.63↑10% | $-4.04↓4% | $-3.88↓12% | $-3.46 |
| Gross Margin | 72.3%↑3% | 74.2%↑4% | 72.8%↑2% | 70.9%↑3% | 70.6%↑2% | 68.9%↑2% | 67.3%↓2% | 68.5%↑4% | 66.2% |
| Operating Margin | -5.7%↑37% | -14.7%↓236% | -1.1%↑89% | -8.1%↑60% | -7.7%↑61% | -19.5%↑23% | -25.4%↑8% | -27.7%↑11% | -31.0% |
| ROE | -21.8%↑48% | — | — | — | -29.2%↑77% | -124.6%↓112% | -58.7%↓21% | -48.4%↓34% | -36.3% |
| Total Debt | -- | -- | -- | -- | -- | -- | $35.0M | $34.9M↑64% | $21.4M |
| Shareholders' Equity | $177.1M↑45% | $177.1M↑45% | $186.0M↑79% | $161.2M↑86% | $152.7M↑68% | $90.9M↓57% | $210.1M↓12% | $239.8M↓14% | $279.5M |
| Current Ratio | 3.57↓23% | 3.57↓23% | 3.85↓23% | 5.17↓10% | 4.63↓21% | 5.82↑171% | 2.15↓34% | 3.24↓7% | 3.48 |
| Debt / Equity | — | — | — | — | — | — | 0.17↑14% | 0.15↑91% | 0.08 |
| Operating Cash Flow | $55.6M↓25% | $4.4M↓87% | $51.1M↑85% | -$26.2M↓232% | $80.9M↑2285% | $3.4M↑107% | -$50.1M↓118% | -$23.0M↑39% | -$37.8M |
| Free Cash Flow | $7.4M↓77% | -$11.5M↓158% | $37.5M↑117% | -$33.1M↓91% | $34.5M↑213% | -$30.6M↑66% | -$90.5M↓71% | -$52.8M↑20% | -$65.8M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
IRTC vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |